SEARCH BUTTON
HOME > IQS TECH TRANSFER > TEAM > José I. Borrell Bilbao, PhD

José I. Borrell Bilbao, PhD

Head of GQF Group - Professor
+34932672000

Design of new synthetic methodologies

  • Design, synthesis and biological evaluation of new inhibitors of GPCR, TK and RTK (cancer), HIV (AIDS), HCV (Hepatitis C) and Myotonic Dystrophy.
  • Design of new synthetic methodologies for heterocyclic systems based on microwaves.

COORDINATOR:

GQF

Grup de Química Farmacèutica

School of Engineering

Pharmaceutical Chemistry Group

The research focuses on two main areas: New Drugs in Biomedicine and Health Sciences and Flow Chemistry Processes.

LATEST PROJECTS

DisX4lymph (Interrupción de la interacción estroma-tumor en linfoma B utilizando inhibidores CXCR4 y degradadores IRAK4)

Diseño y síntesis de inhibidores alostéricos de CXCR4 y degradadores de IRAK4 como potencial tratamiento de linfoma de células B.
Funding Agency:
Research Group Link:
Pharmaceutical Chemistry Group (GQF)

PANCTKI (Nuevos inhibidores multidiana en terapia del cancer de pancreas)

Inhibidores de Tirosina Quinasas Duales en Cáncer de Páncreas: Cribado Virtual, Síntesis, Evaluación Biológica in vitro (2D y 3D) e in vivo.
Funding Agency:
Research Group Link:
Pharmaceutical Chemistry Group (GQF)

ProteoBlood (Red cooperativa franco-española para el análisis de proteinopatías y el desarrollo de terapias individualizadas en cánceres hematológicos)

Estudio de la homeostasis proteica en los dos subtipos de leucemia y linfoma.
Funding Agency:
Research Group Link:
Pharmaceutical Chemistry Group (GQF)
Search more projects

LINKED NEWS

News

New Therapies to Treat Leukaemia

08/07/2022
IQS has participated in the European project PROTEOblood, a cross-border project with the aim of studying and seeking new leukaemia and lymphoma treatments through understanding protein degradation and destruction cycles.
READ FULL NEW
News

Pharmacokinetic and Efficacy Studies

27/07/2021
IQS and the company Xenopat recently signed a collaboration agreement to carry out joint research projects concerning cancer and offer services to third parties by combining both entities' experience, including ADME-Tox, computational prediction, and in vivo efficacy studies, among other pharmacokinetic studies.
READ FULL NEW
Search all news